लोड हो रहा है...
Nintedanib in advanced NSCLC: management of adverse events
Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel has a manageable safety profile in adenocarcinoma NSCLC patie...
में बचाया:
| में प्रकाशित: | Lung Cancer Manag |
|---|---|
| मुख्य लेखक: | |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Future Medicine Ltd
2016
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6322586/ https://ncbi.nlm.nih.gov/pubmed/30643547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt.15.33 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|